X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (23) 23
prostate cancer (19) 19
humans (18) 18
male (16) 16
middle aged (13) 13
cancer (12) 12
patients (12) 12
aged (11) 11
metastasis (11) 11
female (9) 9
metastases (9) 9
psma (9) 9
therapy (9) 9
treatment outcome (9) 9
prostate (8) 8
radioligand therapy (8) 8
retrospective studies (8) 8
survival (8) 8
nuclear medicine (7) 7
oncology (7) 7
adult (6) 6
antigens (6) 6
castration (6) 6
radiology, nuclear medicine & medical imaging (6) 6
tumors (6) 6
ligands (5) 5
radioisotopes - therapeutic use (5) 5
safety (5) 5
toxicity (5) 5
aged, 80 and over (4) 4
cardiology (4) 4
care and treatment (4) 4
dipeptides - therapeutic use (4) 4
dosimetry (4) 4
hematology (4) 4
heterocyclic compounds, 1-ring - therapeutic use (4) 4
imaging / radiology (4) 4
krebs (4) 4
management (4) 4
medicine & public health (4) 4
orthopedics (4) 4
prostata (4) 4
prostatic neoplasms, castration-resistant - radiotherapy (4) 4
radiopharmaceuticals - therapeutic use (4) 4
social sciences (4) 4
survival analysis (4) 4
abridged index medicus (3) 3
american-college (3) 3
anemia (3) 3
antigen (3) 3
bone neoplasms - radiotherapy (3) 3
bone neoplasms - secondary (3) 3
cancer therapies (3) 3
diagnosis (3) 3
lu-177 (3) 3
lu-177-psma-617 (3) 3
melanoma (3) 3
membran (3) 3
multidisciplinary sciences (3) 3
octreotide - analogs & derivatives (3) 3
octreotide - therapeutic use (3) 3
organometallic compounds (3) 3
prostate-specific antigen (3) 3
prostatic neoplasms - radiotherapy (3) 3
prostatic neoplasms, castration-resistant - pathology (3) 3
prrt (3) 3
psychology (3) 3
psykologi (3) 3
radiation therapy (3) 3
radioisotopes (3) 3
recurrence (3) 3
reproducibility of results (3) 3
research paper (3) 3
samhällsvetenskap (3) 3
thrombopenia (3) 3
time factors (3) 3
tomography (3) 3
toxizität (3) 3
tumor markers (3) 3
177 lu (2) 2
177lu (2) 2
alkaline phosphatase (2) 2
analysis (2) 2
anticancer properties (2) 2
antineoplastic agents - therapeutic use (2) 2
behavioral sciences (2) 2
biomarkers (2) 2
bone metastases (2) 2
business (2) 2
cell biology (2) 2
cell proliferation (2) 2
chemical sciences (2) 2
chemistry, multidisciplinary (2) 2
climate change (2) 2
climatic changes (2) 2
combination (2) 2
combined modality therapy (2) 2
creatinine (2) 2
cycles (2) 2
cytotoxicity (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10093, pp. 457 - 468
Summary Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MODIFYING ANTIRHEUMATIC DRUGS | NECROSIS-FACTOR | PLACEBO | JANUS KINASE INHIBITOR | INADEQUATE RESPONSE | LONG-TERM SAFETY | PLUS METHOTREXATE | AMERICAN-COLLEGE | OPEN-LABEL | COMBINATION | Antirheumatic Agents - administration & dosage | Humans | Middle Aged | Male | Methotrexate - therapeutic use | Adalimumab - adverse effects | Arthritis, Rheumatoid - drug therapy | Pyrroles - administration & dosage | Antirheumatic Agents - adverse effects | Pyrroles - adverse effects | Adult | Female | Drug Therapy, Combination | Pyrroles - therapeutic use | Antirheumatic Agents - therapeutic use | Severity of Illness Index | Piperidines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Pyrimidines - administration & dosage | Treatment Outcome | Methotrexate - adverse effects | Adalimumab - therapeutic use | Adalimumab - administration & dosage | Piperidines - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Methotrexate - administration & dosage | Rheumatoid factor | Care and treatment | Analysis | Clinical trials | Arthritis | Pharmaceutical industry | Methotrexate | Rheumatology | Patients | Evidence-based medicine | Studies | Rheumatoid arthritis | Monoclonal antibodies | Rheumatism | TNF inhibitors | Janus kinase | Tumor necrosis factor-TNF | Safety | Drug therapy | Drug dosages
Journal Article
Journal Article
Journal Article
European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, 08/2017, Volume 44, Issue 9, pp. 1473 - 1479
Journal Article
European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, 02/2018, Volume 45, Issue 2, pp. 243 - 246
Purpose Radioligand therapy (RLT) using Lutetium-177 labeled PSMA-617 (Lu-PSMA) ligand is a new therapeutic option for salvage therapy in heavily pretreated... 
mCRPC | PSMA | Prostate cancer | Prostate-specific membrane antigen | Therapy | Delayed response | Salvage | Castration | Metastasis | Radiation therapy | Prostate | Patients | Lutetium | Cancer | Metastases
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2019, Volume 380, Issue 4, pp. 347 - 357
Journal Article
The Prostate, ISSN 0270-4137, 01/2020, Volume 80, Issue 1, pp. 17 - 27
Background Currently, prostate‐specific membrane antigen‐radioligand therapy (PSMA‐RLT) is considered a last‐line treatment option in advanced... 
prostate cancer | PSMA | tumor markers | radioligand therapy | Alkaline phosphatase | Antigens | Tumor markers | Phosphatase | Survival | L-Lactate dehydrogenase | Metastases | Castration | Medical prognosis | Gastrin | Biomarkers | Lactic acid | Prostate cancer | Biochemical markers
Journal Article
European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, 07/2017, Volume 44, Issue 7, pp. 1207 - 1214
Purpose Peptide receptor radionuclide therapy (PRRT) is an effective therapy in patients with a somatostatin receptor-positive neuroendocrine tumour (NET).... 
PRRT | Neuroendocrine tumours | Relapse therapy | Lu-octreotate | Creatinine | Hematology | Laboratories | Toxicity | Thrombocytes | Radioisotopes | Leukocytes | Radiation therapy | Patients | Survival | Lutetium isotopes | Hemoglobin | Patient safety | Somatostatin | Platelets | Tumors | Index Medicus
Journal Article
European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, 2018, Volume 46, Issue 5, pp. 1073 - 1080
Background Data are sparse regarding the feasibility of radioligand therapy (RLT) with [Lu-177]Lu-PSMA-617 as a retreatment. We aimed to assess the outcome and... 
Recurrence | PSMA | Radioligand therapy | CRPC | Prostate cancer | Lutetium-177 | SURVIVAL | DIAGNOSIS | MEMBRANE ANTIGEN PSMA | GUIDELINE | LU-177-PSMA-617 RADIOLIGAND THERAPY | CYCLES | EXPRESSION | DOSIMETRY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Therapy | Antigens | Hematology | Anemia | Toxicity | Feasibility studies | Survival | Patients | Metastases | Thrombopenia | Mathematical analysis | Lutetium isotopes | Safety | Prostate | Cancer | Tumors
Journal Article
Molecules (Basel, Switzerland), ISSN 1420-3049, 12/2019, Volume 24, Issue 24, p. 4561
Journal Article
JOURNAL OF PORPHYRINS AND PHTHALOCYANINES, ISSN 1088-4246, 12/2019, Volume 23, Issue 11-12, pp. 1241 - 1250
Porphyrins and phthalocyanines are photosensitizers (PS) that are used in clinical imaging, detection of cancer cells and are particularly applied in... 
PDT | lectins | GOLD(III) PORPHYRIN COMPLEX | MICROWAVE IRRADIATION | WHEAT-GERM-AGGLUTININ | CHEMISTRY, MULTIDISCIPLINARY | CHLORIN-TYPE PHOTOSENSITIZER | GROWTH-FACTOR RECEPTOR | CONCANAVALIN-A | targeting | IN-VITRO | ANTICANCER DRUGS | PLANT-LECTINS | CARBOHYDRATE-BINDING | Medicinal Chemistry | Chemical Sciences
Journal Article